maturation inhibitor

maturation inhibitor

An antiretroviral agent that inhibits viral replication by disrupting late Gag processing, which is required for the structural rearrangement of viral maturation, a key step in the maturation of viral particles into mature, infectious virions.

Maturation inhibitors (e.g., PA-457) prevent virus maturation by interrupting the conversion of the capsid precursor (p25) to a mature capsid protein (p24), resulting in the formation of defective, noninfectious virus particles.
Mentioned in ?
References in periodicals archive ?
The second late stage asset is a maturation inhibitor (BMS-955176), and is currently in phase IIb development for both treatment-naive and treatment experienced patients.
A back-up maturation inhibitor candidate (BMS-986173) is also included in the purchase.
The Bristol-Myers Squibb clinical stage HIV pipeline reportedly includes an attachment inhibitor (BMS-663068) that is being investigated in Phase III as a therapeutic option for heavily treatment-experienced patients as well as a maturation inhibitor (BMS-955176) that is being investigated in Phase IIb development for treatment-naive and treatment-experienced patients.
Other maturation-preventing factors in follicular fluid are oocyte maturation inhibitor (57) and hypoxanthine, (58) which acts only in combination with cAMP.
In vitro resistance to HIV-1 maturation inhibitor PA-457 (bevirimat).
Food and Drug Administration for the company's second-generation HIV maturation inhibitor, PA-1050040.
released results of a small, 10-day human trial of the maturation inhibitor PA-457, the first time more than a single dose of this compound has been tested in HIV-positive people.
PA-457: A possible new kind of drug called a "maturation inhibitor" interrupts the HIV life cycle at a late step, causing "immature" (non-infectious) viruses to be produced.
Assets in preclinical and discovery phases of development including a novel biologic (BMS-986197) with a triple mechanism of action, a further maturation inhibitor, an allosteric integrase inhibitor and a capsid inhibitor.
Bevirimat (Panacos Pharmaceuticals) is an HIV maturation inhibitor. A Phase IIb study (Study 203) was performed on five treatment-experienced patient cohorts with doses ranging up to 400 mg/day.
In 2014, He received the prestigious James Palmer Award for excellence in drug development (BMS R&D award), especially for his leadership in accelerating the pace of innovation, and his team's accelerated development of HIV-1 Maturation Inhibitors.
There are also other drugs in the integrase and CCR5 inhibitor classes that are in development, and additional promising new classes, such as maturation inhibitors, are being actively evaluated in clinical trials.